These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9450777)

  • 21. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
    Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
    Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients.
    Gibbs E; Oger J
    J Neuroimmunol; 2007 Oct; 190(1-2):146-50. PubMed ID: 17825927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
    Dubois B; Leary SM; Nelissen I; Opdenakker G; Giovannoni G; Thompson AJ
    J Neurol; 2003 Sep; 250(9):1037-43. PubMed ID: 14504963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy.
    Trojano M; Paolicelli D; Zimatore GB; De Robertis F; Fuiani A; Di Monte E; Livrea P
    Neurol Sci; 2005 Dec; 26 Suppl 4():S179-82. PubMed ID: 16388354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
    Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
    Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD95/Fas expression on peripheral blood T lymphocytes in patients with multiple sclerosis: effect of high-dose methylprednisolone therapy.
    Petelin Z; Brinar V; Petravic D; Zurak N; Dubravcic K; Batinic D
    Clin Neurol Neurosurg; 2004 Jun; 106(3):259-62. PubMed ID: 15177780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
    Fernández O; Antigüedad A; Arbizu T; Burgués S; Capdevila A; de Castro P; Correa de Sá JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X; Zarranz JJ
    Rev Neurol; 1999 Dec 16-31; 29(12):1093-9. PubMed ID: 10652728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of interferon beta in relapsing-remitting multiple sclerosis.
    Etheridge LJ; Beverley DW; Ferrie C; McManus E
    Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sørensen PS; Christensen T; Frederiksen J; Ravnborg M; Jensen K; Heltberg A; Kristensen O; Stenager E; Petersen T; Hansen T;
    Neurology; 2006 Apr; 66(7):1056-60. PubMed ID: 16510769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of interferon beta: differences among products.
    Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
    J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 38. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
    Trojano M; Avolio C; Liuzzi GM; Ruggieri M; Defazio G; Liguori M; Santacroce MP; Paolicelli D; Giuliani F; Riccio P; Livrea P
    Neurology; 1999 Oct; 53(7):1402-8. PubMed ID: 10534242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes.
    Munker R; Midis G; Owen-Schaub L; Andreff M
    Leukemia; 1996 Sep; 10(9):1531-3. PubMed ID: 8751476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis.
    Zipp F; Otzelberger K; Dichgans J; Martin R; Weller M
    J Neuroimmunol; 1998 Jun; 86(2):151-4. PubMed ID: 9663560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.